Overview
The goal of this clinical trial is to test ISA104 in patients with chronic hepatitis B. The main question[s] it aims to answer are:
- How safe is ISA104?
- Does ISA104 induce immunity against hepatitis B virus?
Different doses of the vaccine ISA104 will be administered to participants. These participants are chronic HBV patients being actively treated with antiviral drugs.
Researchers will compare the ISA104 vaccine to a placebo.
Eligibility
Inclusion Criteria:
- cHBV
- Active treatment with NUCs and HBV DNA < limit of quantification
Exclusion Criteria:
- Immune-compromised
- Evidence of liver cirrhosis